logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Zhisheng Group Holdings (08370) has reduced 817 million shares due to a 10-for-1 stock consolidation benchmark.

date
18:25 15/02/2024
avatar
GMT Eight
Zhisheng Group Holdings (08370) issued an announcement regarding a "10 to 1" stock consolidation exercise on February 14, 2024.
"Dynamically Rising Holding Group Limited (08370) announced that it will reduce 817 million shares on February 14, 2024, due to a "10-for-1" stock consolidation."
Related Articles
China Stock
Sinolink: Domestic computing power chain is expected to usher in a golden age. We remain optimistic about the high prosperity of the computing power chain market.
US Stock
Weight reduced by 22.5%! Roche's GLP-1 new drug approved for clinical use in China for the first time.
China Stock
Annual revenue exceeding 3 billion, is Cathay Biotech Inc. (688065.SH) truly a scarce target?
Sinolink: Domestic computing power chain is expected to usher in a golden age. We remain optimistic about the high prosperity of the computing power chain market.
China Stock
Weight reduced by 22.5%! Roche's GLP-1 new drug approved for clinical use in China for the first time.
US Stock
Annual revenue exceeding 3 billion, is Cathay Biotech Inc. (688065.SH) truly a scarce target?
China Stock
RECOMMEND
U.S. Ends Offensive Against Iran as Trump Suspends Freedom Plan
U.S. Ends Offensive Against Iran as Trump Suspends Freedom Plan
icon
07/05/2026
China’s Humanoid Robot “Seven Little Dragons” Confront Diverging Strategies and Challenges
China’s Humanoid Robot “Seven Little Dragons” Confront Diverging Strategies and Challenges
icon
07/05/2026
Hong Kong Faces HKD 780 Billion Unlock Wave Amid IPO Boom
Hong Kong Faces HKD 780 Billion Unlock Wave Amid IPO Boom
icon
07/05/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.